Leica Biosystems agreed to acquire Statlab Medical Products to expand Danaher’s diagnostics and anatomical pathology portfolio. The deal strengthens Leica’s consumables and instrument footprint in pathology workflows. Financial terms were not disclosed, but RBC Capital Markets analyst Dan Leonard estimated the transaction could exceed $1 billion. The strategic logic is consistent with ongoing consolidation in lab instrumentation and pathology supply chains. For the biotech and clinical research ecosystem, larger integrated pathology platforms can tighten integration between testing workflows and downstream companion diagnostics and research use cases.